CLINICAL TRIALS PROFILE FOR LATREPIRDINE
✉ Email this page to a colleague
Clinical Trials for Latrepirdine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00912288 ↗ | A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease | Terminated | Medivation, Inc. | Phase 3 | No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine. |
NCT00912288 ↗ | A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease | Terminated | Pfizer | Phase 3 | No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine. |
NCT00954590 ↗ | A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease | Terminated | Pfizer | Phase 3 | The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Latrepirdine
Condition Name
Clinical Trial Locations for Latrepirdine
Trials by Country
Clinical Trial Progress for Latrepirdine
Clinical Trial Phase
Clinical Trial Sponsors for Latrepirdine
Sponsor Name